GlaxoSmithKline plc (GSK), with a market cap of $103 billion, is recognized as the world's largest vaccine manufacturer and is currently working on several COVID-19 vaccines. While this area of the business has commanded most of the headlines, GSK has a broader immunology portfolio and treatment pipeline focusing on HIV, cancer, and respiratory conditions. Separately, the company's consumer healthcare products segment includes many market-leading brands of over-the-counter medications. While the latest Q2 results were slightly weaker than expected, we think the company maintains a positive outlook with solid fundamentals and is an overall